ThermoDox

DRUG5 trials

Conditions

Colon Cancer Liver MetastasisHepatocellular CarcinomaLiver NeoplasmsPancreatic Cancer MetastaticPancreatic Cancer Non-resectablePancreatic Cancer Stage IVPancreatic Ductal Adenocarcinoma

Phase 1

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

CompletedNCT00441376

ImunonHepatocellular Carcinoma, Liver Neoplasms

Start: 2007-02-28End: 2009-12-31Updated: 2019-02-07

PanDox: Targeted Doxorubicin in Pancreatic Tumours

WithdrawnNCT04852367

University of OxfordPancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV +1

Start: 2021-06-16End: 2023-03-30Updated: 2023-04-12

Phase 2

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

TerminatedNCT01464593

ImunonColon Cancer Liver Metastasis

Start: 2011-09-30End: 2013-06-30Updated: 2022-10-13

Phase 3

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

CompletedNCT00617981

ImunonHepatocellular Carcinoma

Start: 2008-05-31End: 2016-08-31Updated: 2024-05-03

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

CompletedNCT02112656

ImunonHepatocellular Carcinoma

Start: 2014-06-30End: 2020-04-27Updated: 2024-08-20

Related Papers

Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.

2023-09-2313 citations

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.

2018-07-11150 citations

Standardized radiofrequency ablation (sRFA) ≥ 45 minutes (m) plus lyso-thermosensitive liposomal doxorubicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: A retrospective analysis of phase III HEAT study.

Journal of Clinical Oncology2014-05-208 citations